Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
The non-nucleoside analog reverse transcriptase inhibitor efavirenz is one of the most common components of HAART. Neuropsychiatric symptoms are frequently reported in patients taking efavirenz-based regimens. These symptoms are usually transient, although they can sometimes persist for up to two years after initiation of treatment. This review describes in detail the most common neuropsychiatric symptoms related to efavirenz, outlines relevant and recent findings on this agent, and suggests possible interventions based on neurobehavioral results. Different recommendations on the assessment of efavirenz-related adverse events are also provided.
Muñoz-Moreno
José A
JA
Lluita Contra la SIDA Foundation - Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain. jmunoz@flsida.org
Fumaz
Carmina R
CR
Ferrer
Maria J
MJ
González-García
Marian
M
Moltó
José
J
Negredo
Eugènia
E
Clotet
Bonaventura
B
D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines / Q000009:adverse effects* / Q000627:therapeutic use; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz